Evidence map›Paper›PMID 32115263›Full record

ArticleEuropean urology2020

Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study.

Yiannis Philippou, Andrew S Protheroe, Richard J Bryant

Abstract readComment
PubMed Publisher
In one paragraph

Article in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yiannis PhilippouDepartment of Oncology, University of Oxford, Oxford, UK.
Andrew S ProtheroeDepartment of Oncology, University of Oxford, Oxford, UK; Department of Oncology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Richard J BryantNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Department of Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: richard.bryant@nds.ox.ac.uk.
Churchill Hospital · GBUniversity of Oxford · GB

Funding

Cancer Research UK 22748Cancer Research UK C39297/A22748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, ImmunologicalProstatic Neoplasms, Castration-ResistantAntibodies, Monoclonal, HumanizedHumansMaleAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumab

Identifiers

PMID32115263
OpenAlexW3007288789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.